Regulatory regulatory approval

FDA Accepts Ultragenyx UX111 BLA for Sanfilippo

Analysis based on 7 articles · First reported Apr 02, 2026 · Last updated Apr 06, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The acceptance of the BLA for UX111 by the United States===Food and Drug Administration is a positive development for the biotechnology sector, particularly for Ultragenyx. It signals potential market entry for a novel gene therapy, which could lead to increased investor confidence in companies developing treatments for rare diseases.

Biotechnology Pharmaceuticals

Event Summary

Ultragenyx announced that the U.S. United States===Food and Drug Administration (FDA) has accepted for review its resubmitted Biologics License Application (BLA) for UX111 (rebisufligene etisparvovec) AAV9 gene therapy. This therapy is intended to treat Sanfilippo syndrome Type A (MPS IIIA), a rare and fatal neurodegenerative disease. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of September 19, 2026. If approved, UX111 would be the first therapy for this condition, offering a significant breakthrough for patients and their families. The BLA includes updated long-term clinical data, showing durable treatment effects and an acceptable safety profile. The therapy was originally developed by Abeona Therapeutics and will be manufactured in the United States by Andelyn Biosciences and Ultragenyx's own facility.

Key Actions

95 United States===Food and Drug Administration accepted Biologics License Application for UX111 Ultragenyx

90 Ultragenyx resubmitted Biologics License Application for UX111 United States===Food and Drug Administration

85 United States===Food and Drug Administration set PDUFA action date for UX111 Ultragenyx

30 Abeona Therapeutics developed UX111 and transferred to Ultragenyx Ultragenyx

Entities Involved

stock

Ultragenyx

Ultragenyx announced that the U.S. United States===Food and Drug Administration accepted its Biologics License Application for UX111, a gene therapy for Sanfilippo syndrome Type A. This brings the company closer to potentially launching the first approved therapy for this rare disease, which could significantly boost its market position and revenue.

Importance 100 Sentiment 70

govactor

United States===Food and Drug Administration

The United States===Food and Drug Administration accepted Ultragenyx's BLA for UX111 and set a PDUFA action date, indicating progress in the regulatory review process for a potentially groundbreaking therapy.

Importance 80 Sentiment 0

per

Emil D. Kakkis

As CEO and President of Ultragenyx, Emil D. Kakkis expressed appreciation for the United States===Food and Drug Administration's acceptance of the BLA for UX111, highlighting the significance of this step towards a first-ever therapy for Sanfilippo syndrome Type A.

Importance 50 Sentiment 60

stock

Abeona Therapeutics

Abeona Therapeutics originally developed UX111 before transferring it to Ultragenyx for further development. This event highlights Abeona Therapeutics' contribution to the therapy's early stages.

Importance 30 Sentiment 20

priv

Andelyn Biosciences

Andelyn Biosciences is designated as one of the manufacturing facilities for UX111 in the U.S. if the therapy is approved, indicating a potential increase in its operational activities.

Importance 20 Sentiment 10

cnt

United States

UX111, if approved, will be manufactured entirely within the United States, at facilities in Columbus, Ohio and Bedford, Massachusetts, contributing to domestic biopharmaceutical production.

Importance 10 Sentiment 0

Relationships

United States===Food and Drug Administration related ↔ Ultragenyx

Emil D. Kakkis related ↔ Ultragenyx

Andelyn Biosciences related ↔ Ultragenyx

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard